Evotec partners with Odyssey Therapeutics on AI-enabled autoimmune, inflammatory drug discovery
Reuters2026/08/06 05:37- Evotec entered a strategic R&D collaboration with Odyssey Therapeutics to discover new small-molecule treatments for autoimmune and inflammatory diseases.
- Odyssey will use Evotec’s AI-enabled discovery platform, screening capabilities, and compound libraries to identify and validate hit series across multiple targets.
- Evotec is eligible for milestone payments tied to delivery of validated hit series for each target; financial terms were not disclosed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
